Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Mutation-guided finite-duration acalabrutinib plus venetoclax for relapse after first-line finite-duration COVALENT Bruton tyrosine kinase inhibitor plus venetoclax‒based combination therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: Phase 2 MAVRiC study

View Full Paper
Ask AI
Bookmark
Share

Authors

MHMoana HodariJMJiefen MunleyRHRichard Hermann

Discussion

Loading...

Member takes

Overview

Phase 2 trial assesses efficacy of mutation-guided acalabrutinib plus venetoclax after relapse in CLL/SLL, suggesting improved outcomes for novel targeted therapies.

Key Points

  • To evaluate the efficacy and safety of mutation-guided finite-duration combination therapy in patients with relapsed CLL/SLL.
  • Phase 2, open-label, multicenter study of patients with relapsed CLL/SLL following treatment with BTKi + BCL-2i.
  • Patients receive acalabrutinib and venetoclax based on genetic risk (IGHV and TP53 mutations).
  • The study includes 80 patients globally, with treatment outcomes monitored over 5 years.
  • Primary endpoint is overall response rate after 12 cycles, assessed per iwCLL 2018 criteria.
  • Secondary endpoints include progression-free survival and rates of minimal residual disease at 3 months post-treatment.

Cite This Study

Hodari et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1bbhttps://doi.org/10.1182/blood-2025-3912
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated Mantle Cell Lymphoma (MAVO)2025 · 8 citations
  2. 2Sonrotoclax (BGB-11417) + zanubrutinib (SZ) vs venetoclax + acalabrutinib (AV) in treatment-naive chronic lymphocytic leukemia (TN CLL): A phase 3 randomized trial design (CELESTIAL-TNCLL-2).2026
  3. 3Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis2024 · 28 citations
  4. 4Bendamustine/Rituximab Induction Followed by Venetoclax/Rituximab Consolidation in Frontline Treatment of Chronic Lymphocytic Leukemia: A Phase 2 Multi‐Center Study2026
  5. 5Acalabrutinib plus venetoclax and rituximab in patients with treatment-naive (TN) mantle cell lymphoma (MCL): Results from the Phase 2 TrAVeRse study2025 · 12 citations